Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases.

Autor: Martini PG; Department of Protein Expression and Purification Research, Shire Human Genetic Therapies Inc, 700 Main Street, Cambridge, MA 02139, USA. pmartini@shire.com, Cook LC, Alderucci S, Norton AW, Lundberg DM, Fish SM, Langsetmo K, Jönsson G, Lood C, Gullstrand B, Zaleski KJ, Savioli N, Lottherand J, Bedard C, Gill J, Concino MF, Heartlein MW, Truedsson L, Powell JL, Tzianabos AO

Publikováno v: BMC immunology [BMC Immunol] 2010 Aug 20; Vol. 11, pp. 43. Date of Electronic Publication: 2010 Aug 20.